LydiaRx
About

Built to make a nation's genome its own.

LydiaRx exists so that countries can build population genomics programmes they own. Secure. In-country. Governed by their own people. Built for the populations they serve.

Why LydiaRx

Why we started LydiaRx.

Genomic medicine has been built on a narrow slice of humanity. The reference data that shapes drug development, dosing and disease-risk models comes overwhelmingly from populations of European ancestry. The populations with the most decisive biology (large, consanguineous, genetically distinct) are the least represented. The countries that hold them have too often been offered a poor choice. Export the data to someone else's cloud, or do nothing.

We founded LydiaRx to give governments a third option. We build the sovereign data layer for national genome programmes, and the evidence layer that turns population genomics and regulatory data into decision-grade, provenance-backed knowledge. We are a small core team by design: we hold the mandate, the legal architecture, the supply chain and the governance; national institutions collect, sequence and analyse, and the country owns the result. Headquartered in the United Kingdom, with a local operating presence formed in each programme country.

What we believe

Six convictions, and what each one makes us do.

A country's genome is a national asset, not a dataset for sale.

So we take no ownership of samples or data, ever. The State owns; a public institution holds; a national-majority committee decides.

Analysis should travel. Data should not.

So we built a platform where researchers bring their questions to the data. They leave with answers, never with copies.

The operator must be as constrained as the guest.

So we run the environment under the same controls as every partner, on a ledger the State verifies without our help.

Capacity that is given lapses. Capacity that pays for itself stays.

So we design every programme so that governed research access funds the centre after the pilot and returns a share to the State.

Trust is earned by delivering something real, to a standard that can be inspected.

So we finance the first step privately, publish every governance document, and submit to two independent audits.

Every claim should be checkable.

So we name our people and our company number. We invite you to verify both.

The journey

Twelve months, in order.

  1. Autumn 2025

    The evidence layer takes its first commercial mandate

    An AI-strategy engagement for a clinical-stage cardiometabolic company.

  2. October 2025

    The bench forms

    Dr Shahid Hanif, formerly Head of Health Data and Outcomes at the ABPI, joins as adviser.

  3. January 2026

    The Pakistan National Genome Programme takes shape

    One million whole genomes over four phases, delivered in-country and owned by the State.

  4. Spring 2026

    Architecture, financing and independent oversight

    Programme architecture and financing structure built. The independent Governance and Ethics Board convened under Dr Andrew Roddam, with Pakistan-resident clinical and academic co-leads.

  5. June 2026

    Concession-grade drafting

    Project agreements and the data-sovereignty and licence framework drafted and in negotiation. The Sovereignty and Trust Charter written.

  6. July 2026

    A protected platform

    United States provisional patent applications filed for Atlas, Prism and Phylax. Term sheet agreed for the locally majority-owned national joint venture.

  7. September 2026

    The demonstration pilot

    Proposal finalised: 400 whole genomes and the first Pakistani pangenome. Ready for ethics submission.

  8. Autumn 2026

    The bench grows, and the model travels

    Advisers from the 100,000 Genomes Project, Genomics England and Oxford translational research join. Programmes proposed or in discussion in six countries across South Asia, the Gulf, the Indian Ocean, Türkiye, the Balkans and Southern Africa.

Partners and reach

Who stands with us, and where we can act.

  • Our sequencing partner. A long-read sequencing platform already deployed in national programmes on three continents, with in-country training and a scientist resident on site for the first months of a pilot.
  • Governments and institutions. The Government of Pakistan, to which a one-million-genome programme has been proposed; governments in the Maldives, Albania and Türkiye, to which proposals have been presented; a Saudi programme designed with in-Kingdom partners; South Africa's national genome programme community.
  • The UK genomics establishment. Our people have led or helped found Our Future Health, the 100,000 Genomes Project and Genomics England, and chair SNOMED International. Our governance is written to the CIOMS guidelines and the Declaration of Helsinki.
  • Industry. The companies that become the research partners of a sovereign cohort are companies our people have run programmes with: Regeneron, Pfizer, AstraZeneca, GSK, Novartis, Genentech/Roche, Cancer Research UK, IQVIA and the ABPI. We know what they will ask for before they ask.
  • Bioethics and standards. The Council of Europe's bioethics committee (chaired by our adviser), G7 pathogen-surveillance work, the European regulators our advisers have taken rare-disease and gene-therapy products through, and the GA4GH standards our platform implements.
  • Geography. Headquartered in the United Kingdom, with a local operating presence formed in each programme country; scientific leadership in the United States; clinical-research and regulatory reach across Europe; delivery presence in Pakistan; a programme ready in the Gulf; programmes proposed from the Balkans and the Indian Ocean to Southern Africa.
  • Finance. Our pilots are privately financed by LydiaRx and the funders and research partners we bring, and the research-access framework gives every phase an income of its own.
How to verify us
  • The company: LydiaRx Ltd, registered in England and Wales, company number 17365784. Directors and filings are at Companies House.
  • The people: each by public record and, with their agreement, by direct conversation.
  • The standard and the design: the Charter, consent suite and governance documents published in full; no public funds sought to start; no sample or data leaving the country; national-majority oversight of access; independent audits, published.

Talk to the people who built it.

We are a small team. A briefing is with a founder.